Stock PYC PYC THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Market Closed - Australian S.E.
Other stock markets
 02:10:46 2024-04-30 am EDT 		5-day change 1st Jan Change
0.097 AUD +5.43% Intraday chart for PYC Therapeutics Limited +7.78% -11.82%
Apr. 22 Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data MT
Apr. 22 PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PYC THERAPEUTICS LIMITED Stock PYC Therapeutics Limited
-11.82% 270M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.44% 42.86B
B
MODERNA, INC. Stock Moderna, Inc.
+12.34% 42.74B
B-
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.70% 25.15B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.49% 18.63B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.22% 12.37B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.64% 11.92B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.69% 11.21B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PYC Stock
  4. Ratings PYC Therapeutics Limited